Table 2 Variant SARS-CoV-2 recombinant spike protein constructs

From: Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants

Vaccine construct

Accession #

Mutations from NVX-CoV2373 rS

SARS-CoV-2 Alpha rS (BV2425)

GISAID EPI_ISL_683466

Δ69-70, Δ144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H

SARS-CoV-2 Beta rS (BV2438)

GISAID EPI_ISL_696502

D80A, D215G, L242H, K417N, E484K, N501Y, D614G, A701V

SARS-CoV-2 Gamma rS(BV2443)

GISAID EPI_ISL_833174

L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F

SARS-CoV-2 Delta rS(BV2465)

GISAID EPI_ISL_2133949

T19R, G142D, Δ156, Δ157, R158G, L452R, T478K, D614G, P681R, D950N

SARS-CoV-2 Delta Plus rS(BV2472)

GISAID EPI_ISL_2439552

T19R, G142D, R158G, Δ156, Δ157, W258I, K417N, L452R, T478K, D614G, P681R, D950N

Back to article page